56 results
8-K
KALV
KalVista Pharmaceuticals Inc
7 Mar 24
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
6:38am
base salary and (2) reimbursement for continuation coverage under COBRA for 15 months. If within two years immediately following the consummation … such termination of employment occurs, (3) reimbursement for continuation coverage under COBRA for 21 months (with months 19-21 consisting of a taxable lump sum
8-K
EX-1.1
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
4:32pm
.
Section 7. Reimbursement of Underwriters’ Expenses. If this Agreement is terminated by the Representatives pursuant to Section 6, Section 11
424B5
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
Prospectus supplement for primary offering
4:29pm
and reimbursement status of newly approved products is uncertain; failure to obtain or maintain adequate coverage and reimbursement for new or current products could
424B5
KALV
KalVista Pharmaceuticals Inc
14 Feb 24
Prospectus supplement for primary offering
5:13pm
in others discovering, developing or commercializing competing products before or more successfully than we do;
the insurance coverage and reimbursement … status of newly approved products is uncertain; failure to obtain or maintain adequate coverage and reimbursement for new or current products could
S-8
u72o5vwt jewqaslkcyj
20 Jun 23
Registration of securities for employees
4:13pm
8-K
EX-10.1
83vtp
14 Jun 23
Departure of Directors or Certain Officers
4:30pm
8-K
EX-10.1
sf2al4bp6z b6
27 Dec 22
Entry into a Material Definitive Agreement
6:42am
8-K
EX-1.1
u9b5pt vw
11 Feb 21
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock
4:18pm